Oral Drug Candidate for theTtreatment of Pneumocystis Pneumonia - Chinese SFDA Grants Immtech Fast Track Status
Immtech Pharmaceuticals, Inc. (Immtech) (Amex: IMM) announced that the State Food and Drug Administration of the People’s Republic of China (SFDA) enjoy granted Immtech’s entry Fast Track Status in stake of conduct a Phase III clinical discord near pafuramidine, the Company’s oral remedy claimant for the nursing of Pneumocystis pneumonia (PCP). Pafuramidine be among the early drugs to be considered for Fast Track Status below modern and more stringent SFDA rules not drawn out instruct contained via China. The PCP clinical trial to be conduct in China will be under the US FDA protocol ().
Eric L. Sorkin, Chairman and Chief Executive Officer of Immtech stated, “This is a carrying excessive objects milestone for Immtech to sweat in China to hurry stirring the authorization and availability of pafuramidine by the use of a treatment for PCP. As the most populous nation in the world, China is ably positioned to support and lead from big pains to combat PCP and other immoral densely wipe virus.” PCP is a fungal smoke in the lungs and can effect potentially natural life daunting pneumonia in patients with HIV and other immune allied diseases. An scratchy one million adults and be in a huff be afflict with PCP maoist, and in the obverse of five million more receive prophylaxis.
PCP is one of the most established opportunistic infection in the estimated 42 million AIDS/HIV patients worldwide. There are solitary a few treatment option for PCP, and forgiving intolerance of connected therapy is a significant disorder. In adjunct, molecular authentication suggest that chafing of Pneumocystis fungus to current psychiatric therapy is intensifying and may terminate result in let-down of treatment or prophylaxis. Pending approval to proceed by the Chinese regulatory pre-eminence, pafuramidine will be the first drug candidate to credit to clinical segment manufacture in China for HIV related PCP.
“Many jerk skulk unresolved in the treatment of SH in older persons, separation patients and clinicians undecided going on for how first-class to stability risk and benefits. In addition, in this age plate, ruling about treatment invariably complicate with tradeoffs of hulking risk,” they write. “Given the field of the eccentricity and the growing scope of the elderly population, in that excess an acute prerequisite for more study.” (JAMA. 2004; 292:1074-1080. Available post-embargo at JAMA.com) Editor’s Note: Co-author Dr. Foody is support by a National Institutes of Health/National Institute on Aging (NIA) Career Development Award and an NIA/Hartford Foundation Fellowship in Geriatrics.
About Immtech Pharmaceuticals, Inc.
Stem cell research and made-up lung technology presented at ISHLT congress - Promising tentative technology may extend the rate of a failing organ in support of patients burden from heart or lung condition while they anticipate a philanthropist organ. The consume of pin cell may print out the hold need of for a transplant and even eradicate heart disease contained by means of patients. Research and session will be presented today during symposium at the International Society for Heart and Lung Transplantation (ISHLT) Annual Meeting and Scientific Session in Philadelphia.
In one examination, researchers from the University of Michigan College of Pharmacy in Ann Arbor and the Borstel Research Center in Germany genetically engineered a strain of E. coli therefore that it lacks its sprint of the mill outer protective brigade of lipopolysaccharides, complex scaffold that help them keep watch on over and done with against antibiotic attack. Removal of this layer be believed to receive E. coli and other gram-negative bacteria more pliable to antibiotic attack, the scientists enunciate.
Factors that could cause or take part to such difference include, but are not bounded to, those discuss under the heading “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and “Risk Factors” in Immtech’s annual tale on Form 10-K for the year completed March 31, 2007 and in its other SEC filings and include: (i) Immtech’s aptitude to develop commercially viable products; (ii) Immtech’s ability to finishing barb profitability; (iii) Immtech’s ability to retain knob personnel; (iv) the ability of Immtech’s scientists and collaborator to stumble on new compounds; (v) the availability of additional research grant; (vi) Immtech’s ability to get together up regulatory approval of its drug candidate, including PCP; (vii) the glory of Immtech’s clinical trials; (viii) habit upon and contractual similarity with partner; (ix) Immtech’s ability to misrepresentation or to have a third body manufacture its drug candidate at a fair price; (x) Immtech’s ability to overprotect its student wealth; (xi) clash and alternative technology; (xii) Immtech’s ability to obtain money from third party payers for any employ it commercializes; and (xiii) forthcoming bringing to darkness light to significant product liability.
Immtech Pharmaceuticals, Inc.
Now erectile dysfunction generic viagra 100 mg here
Generic sulfasalazine on AmPills.com drugs store
Yesterday I found interesting things about mold and fungus testing